Access to innovation: Is there a difference in the use of expensive anticancer drugs between French hospitals?
Author
Abstract
Suggested Citation
DOI: 10.1016/j.healthpol.2013.11.006
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Albane Degrassat-Théas & M. Bensadon & C. Rieu & M. Angalakuditi & Claude Le Pen & Pascal Paubel, 2012. "Hospital Reimbursement Price Cap for Cancer Drugs: the French experience in controlling hospital drug expenditures," Post-Print hal-01507735, HAL.
- Albane Degrassat-Théas & M. Bensadon & C. Rieu & M. Angalakuditi & C. Pen & P. Paubel, 2012. "Hospital Reimbursement Price Cap for Cancer Drugs," PharmacoEconomics, Springer, vol. 30(7), pages 565-573, July.
- Gérard de Pouvourville, 2009. "Les hôpitaux français face au paiement prospectif au cas. La mise en œuvre de la tarification à l'activité," Revue économique, Presses de Sciences-Po, vol. 60(2), pages 457-470.
- Cappellaro, Giulia & Ghislandi, Simone & Anessi-Pessina, Eugenio, 2011. "Diffusion of medical technology: The role of financing," Health Policy, Elsevier, vol. 100(1), pages 51-59, April.
- repec:dau:papers:123456789/11666 is not listed on IDEAS
- Joshua Cohen & Laura Faden & Susan Predaris & Brian Young, 2007. "Patient access to pharmaceuticals: an international comparison," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(3), pages 253-266, September.
- Nigel Rice & Andrew Jones, 1997. "Multilevel models and health economics," Health Economics, John Wiley & Sons, Ltd., vol. 6(6), pages 561-575, November.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Rachet-Jacquet, Laurie & Toulemon, Léa & Rochaix, Lise, 2021.
"Hospital payment schemes and high-priced drugs: Evidence from the French Add-on List,"
Health Policy, Elsevier, vol. 125(7), pages 923-929.
- Laurie Rachet-Jacquet & Léa Toulemon & Lise Rochaix, 2021. "Hospital payment schemes and high-priced drugs: Evidence from the French Add-on List," Post-Print halshs-03238834, HAL.
- Laurie Rachet-Jacquet & Léa Toulemon & Lise Rochaix, 2021. "Hospital payment schemes and high-priced drugs: Evidence from the French Add-on List," Institut des Politiques Publiques halshs-03238834, HAL.
- Laurie Rachet-Jacquet & Léa Toulemon & Lise Rochaix, 2021. "Hospital payment schemes and high-priced drugs: Evidence from the French Add-on List," PSE-Ecole d'économie de Paris (Postprint) halshs-03238834, HAL.
- Andrea Gabrio & Catrin Plumpton & Sube Banerjee & Baptiste Leurent, 2022. "Linear mixed models to handle missing at random data in trial‐based economic evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 31(6), pages 1276-1287, June.
- Laudicella, Mauro & Olsen, Kim Rose & Street, Andrew, 2010. "Examining cost variation across hospital departments-a two-stage multi-level approach using patient-level data," Social Science & Medicine, Elsevier, vol. 71(10), pages 1872-1881, November.
- Apostolos Tsiachristas† & Ren頇oudriaan & Wim Groot, 2013. "The welfare effects of innovative pharmaceuticals: an international perspective from the Dutch experience," Applied Economics, Taylor & Francis Journals, vol. 45(9), pages 1219-1226, March.
- Zenelabden, Nouran & Dikgang, Johane, 2021. "Satisfaction with water services delivery in South Africa: the effects of social comparison," EfD Discussion Paper 21-7, Environment for Development, University of Gothenburg.
- Kollerup, Anna & Wadmann, Sarah & Bek, Toke & Kjellberg, Jakob, 2022. "National clinical guidelines and treatment centralization do not guarantee consistency in healthcare delivery. A mixed-methods study of wet age-related macular degeneration treatment in Denmark," Health Policy, Elsevier, vol. 126(12), pages 1291-1302.
- Mousquès, Julien & Renaud, Thomas & Scemama, Olivier, 2010. "Is the "practice style" hypothesis relevant for general practitioners? An analysis of antibiotics prescription for acute rhinopharyngitis," Social Science & Medicine, Elsevier, vol. 70(8), pages 1176-1184, April.
- M. Lippi Bruni & L. Nobilio & C. Ugolini, 2007. "Economic Incentives in General Practice: the Impact of Pay for Participation Programs on Diabetes Care," Working Papers 607, Dipartimento Scienze Economiche, Universita' di Bologna.
- Frank Eijkenaar & René C. J. A. van Vliet, 2014. "Performance Profiling in Primary Care," Medical Decision Making, , vol. 34(2), pages 192-205, February.
- Verniers, Isabel & Stremersch, Stefan & Croux, Christophe, 2011. "The global entry of new pharmaceuticals: A joint investigation of launch window and price," International Journal of Research in Marketing, Elsevier, vol. 28(4), pages 295-308.
- van Dijk, Christel E. & Korevaar, Joke C. & Koopmans, Berber & de Jong, Judith D. & de Bakker, Dinny H., 2014. "The primary–secondary care interface: Does provision of more services in primary care reduce referrals to medical specialists?," Health Policy, Elsevier, vol. 118(1), pages 48-55.
- Martin Halla & Friedrich Schneider & Alexander Wagner, 2013.
"Satisfaction with democracy and collective action problems: the case of the environment,"
Public Choice, Springer, vol. 155(1), pages 109-137, April.
- Martin Halla & Friedrich Schneider & Alexander Wagner, 2008. "Satisfaction with Democracy and Collective Action Problems: The Case of the Environment," Economics working papers 2008-08, Department of Economics, Johannes Kepler University Linz, Austria.
- Halla, Martin & Schneider, Friedrich & Wagner, Alexander F., 2008. "Satisfaction with Democracy and Collective Action Problems: The Case of the Environment," IZA Discussion Papers 3613, Institute of Labor Economics (IZA).
- Sicsic, Jonathan & Le Vaillant, Marc & Franc, Carine, 2012. "Intrinsic and extrinsic motivations in primary care: An explanatory study among French general practitioners," Health Policy, Elsevier, vol. 108(2), pages 140-148.
- repec:spo:wpmain:info:hdl:2441/3018m4nhj18vvr47bolsnnqeqs is not listed on IDEAS
- repec:hal:spmain:info:hdl:2441/3018m4nhj18vvr47bolsnnqeqs is not listed on IDEAS
- Jonas Schreyögg & Tom Stargardt & Oliver Tiemann, 2011. "Costs and quality of hospitals in different health care systems: a multi‐level approach with propensity score matching," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 85-100, January.
- Maximilian H. M. Hatz & Jonas Schreyögg & Aleksandra Torbica & Giuseppe Boriani & Carl R. B. Blankart, 2017. "Adoption Decisions for Medical Devices in the Field of Cardiology: Results from a European Survey," Health Economics, John Wiley & Sons, Ltd., vol. 26(S1), pages 124-144, February.
- Pepijn Vemer & Maureen Rutten-van Mölken, 2013. "The Road Not Taken: Transferability Issues in Multinational Trials," PharmacoEconomics, Springer, vol. 31(10), pages 863-876, October.
- Julia Bonastre & Marc le Vaillant & Gerard de Pouvourville, 2011. "The impact of research on hospital costs of care: an empirical study," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 73-84, January.
- Troels Kristensen & Kim Olsen & Henrik Schroll & Janus Thomsen & Anders Halling, 2014. "Association between fee-for-service expenditures and morbidity burden in primary care," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(6), pages 599-610, July.
- Nils Gutacker & Chris Bojke & Silvio Daidone & Nancy J. Devlin & David Parkin & Andrew Street, 2013.
"Truly Inefficient Or Providing Better Quality Of Care? Analysing The Relationship Between Risk‐Adjusted Hospital Costs And Patients' Health Outcomes,"
Health Economics, John Wiley & Sons, Ltd., vol. 22(8), pages 931-947, August.
- Nils Gutacker & Chris Bojke & Silvio Daidone & Nancy Devlin & David Parkin & Andrew Street, 2011. "Truly inefficient or providing better quality of care? Analysing the relationship between riskadjusted hospital costs and patients’ health outcomes," Working Papers 068cherp, Centre for Health Economics, University of York.
- Stargardt, Tom & Schreyögg, Jonas, 2012. "A framework to evaluate the effects of small area variations in healthcare infrastructure on diagnostics and patient outcomes of rare diseases based on administrative data," Health Policy, Elsevier, vol. 105(2), pages 110-118.
More about this item
Keywords
Hospitals; Patient access; Innovation; Anticancer drugs;All these keywords.
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:116:y:2014:i:2:p:162-169. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.